Cargando…
Pharmacological Prophylaxis of Atrial Fibrillation After Surgical Myocardial Revascularization
INTRODUCTION: Postoperative Atrial Fibrillation (POAF) is associated with a higher rate of postoperative complications and mortality, as well as with longer hospitalization and increased treatment costs. We have designed and performed a randomized, trial of pharmacological prophylaxis in which the e...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Medical Sciences of Bosnia and Herzegovina
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445624/ https://www.ncbi.nlm.nih.gov/pubmed/31097854 http://dx.doi.org/10.5455/medarh.2019.73.19-22 |
_version_ | 1783408233323429888 |
---|---|
author | Osmanovic, Enes Ostojic, Miodrag Avdic, Sevleta Djedovic, Samed Delic, Adnan Kadric, Nedzad Terzic, Amar Avdic-Salihovic, Azra |
author_facet | Osmanovic, Enes Ostojic, Miodrag Avdic, Sevleta Djedovic, Samed Delic, Adnan Kadric, Nedzad Terzic, Amar Avdic-Salihovic, Azra |
author_sort | Osmanovic, Enes |
collection | PubMed |
description | INTRODUCTION: Postoperative Atrial Fibrillation (POAF) is associated with a higher rate of postoperative complications and mortality, as well as with longer hospitalization and increased treatment costs. We have designed and performed a randomized, trial of pharmacological prophylaxis in which the event of interest is POAF. AIM: The aim of this study is to reduce the risk of postoperative, complications associated with this arrhythmia. METHODS: We included 240 stable patients with a coronary heart disease, who were referred to elective surgical revascularization of the myocardium. The patients were assigned into three groups of 80 patients each: group A (BB, beta blocker, comparator), group B (BB+ Amiodarone) and group C (BB + Rosuvastatin). The goal was to establish whether intervention by combination therapy was more useful than a comparator. RESULTS: An event of interest (POAF) has occurred in 66 of the total 240 patients. Number of new POAF cases is the lowest in Group B, 14 (17.5%) compared to 25 (31.25%) new cases in the comparator group, and 27 new cases (33.75%) in group C. Absolute risk reduction was 13.75%, ≈14% less POAF in group B compared to comparator. Relative risk reduction was 56% (RR 0.56, p = 0.04). Number Needed to Treat was 7.27. In group C, 33.75% of patients developed POAF. Absolute risk was insignificantly higher in group C (2.5%, NS) compared to the comparator .The number needed to harm was high, 40. CONCLUSION: The results of our research show that prophylaxis of POAF with combined therapy BB + Amiodarone was the most efficient one. |
format | Online Article Text |
id | pubmed-6445624 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Academy of Medical Sciences of Bosnia and Herzegovina |
record_format | MEDLINE/PubMed |
spelling | pubmed-64456242019-05-16 Pharmacological Prophylaxis of Atrial Fibrillation After Surgical Myocardial Revascularization Osmanovic, Enes Ostojic, Miodrag Avdic, Sevleta Djedovic, Samed Delic, Adnan Kadric, Nedzad Terzic, Amar Avdic-Salihovic, Azra Med Arch Original Paper INTRODUCTION: Postoperative Atrial Fibrillation (POAF) is associated with a higher rate of postoperative complications and mortality, as well as with longer hospitalization and increased treatment costs. We have designed and performed a randomized, trial of pharmacological prophylaxis in which the event of interest is POAF. AIM: The aim of this study is to reduce the risk of postoperative, complications associated with this arrhythmia. METHODS: We included 240 stable patients with a coronary heart disease, who were referred to elective surgical revascularization of the myocardium. The patients were assigned into three groups of 80 patients each: group A (BB, beta blocker, comparator), group B (BB+ Amiodarone) and group C (BB + Rosuvastatin). The goal was to establish whether intervention by combination therapy was more useful than a comparator. RESULTS: An event of interest (POAF) has occurred in 66 of the total 240 patients. Number of new POAF cases is the lowest in Group B, 14 (17.5%) compared to 25 (31.25%) new cases in the comparator group, and 27 new cases (33.75%) in group C. Absolute risk reduction was 13.75%, ≈14% less POAF in group B compared to comparator. Relative risk reduction was 56% (RR 0.56, p = 0.04). Number Needed to Treat was 7.27. In group C, 33.75% of patients developed POAF. Absolute risk was insignificantly higher in group C (2.5%, NS) compared to the comparator .The number needed to harm was high, 40. CONCLUSION: The results of our research show that prophylaxis of POAF with combined therapy BB + Amiodarone was the most efficient one. Academy of Medical Sciences of Bosnia and Herzegovina 2019-02 /pmc/articles/PMC6445624/ /pubmed/31097854 http://dx.doi.org/10.5455/medarh.2019.73.19-22 Text en © 2019 Enes Osmanovic, Miodrag Ostojic, Sevleta Avdic, Samed Djedovic, Adnan Delic, Nedzad Kadric, Amar Terzic, Azra Avdic-Salihovic http://creativecommons.org/licenses/by-nc/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Paper Osmanovic, Enes Ostojic, Miodrag Avdic, Sevleta Djedovic, Samed Delic, Adnan Kadric, Nedzad Terzic, Amar Avdic-Salihovic, Azra Pharmacological Prophylaxis of Atrial Fibrillation After Surgical Myocardial Revascularization |
title | Pharmacological Prophylaxis of Atrial Fibrillation After Surgical Myocardial Revascularization |
title_full | Pharmacological Prophylaxis of Atrial Fibrillation After Surgical Myocardial Revascularization |
title_fullStr | Pharmacological Prophylaxis of Atrial Fibrillation After Surgical Myocardial Revascularization |
title_full_unstemmed | Pharmacological Prophylaxis of Atrial Fibrillation After Surgical Myocardial Revascularization |
title_short | Pharmacological Prophylaxis of Atrial Fibrillation After Surgical Myocardial Revascularization |
title_sort | pharmacological prophylaxis of atrial fibrillation after surgical myocardial revascularization |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445624/ https://www.ncbi.nlm.nih.gov/pubmed/31097854 http://dx.doi.org/10.5455/medarh.2019.73.19-22 |
work_keys_str_mv | AT osmanovicenes pharmacologicalprophylaxisofatrialfibrillationaftersurgicalmyocardialrevascularization AT ostojicmiodrag pharmacologicalprophylaxisofatrialfibrillationaftersurgicalmyocardialrevascularization AT avdicsevleta pharmacologicalprophylaxisofatrialfibrillationaftersurgicalmyocardialrevascularization AT djedovicsamed pharmacologicalprophylaxisofatrialfibrillationaftersurgicalmyocardialrevascularization AT delicadnan pharmacologicalprophylaxisofatrialfibrillationaftersurgicalmyocardialrevascularization AT kadricnedzad pharmacologicalprophylaxisofatrialfibrillationaftersurgicalmyocardialrevascularization AT terzicamar pharmacologicalprophylaxisofatrialfibrillationaftersurgicalmyocardialrevascularization AT avdicsalihovicazra pharmacologicalprophylaxisofatrialfibrillationaftersurgicalmyocardialrevascularization |